Antipodes Partners’s Valaris VAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$72.3M Buy
996,450
+225,458
+29% +$21M 1.33% 36
2026
Q1
$75.6M Buy
770,992
+75,987
+11% +$5.92M 1.46% 33
2025
Q4
$35M Buy
695,005
+114,807
+20% +$6.16M 0.74% 40
2025
Q3
$28.3M Buy
580,198
+573,065
+8,034% +$28M 0.63% 45
2025
Q2
$300K Sell
7,133
-780
-10% -$29.3K 0.01% 58
2025
Q1
$311K Buy
7,913
+1,568
+25% +$67.2K 0.01% 54
2024
Q4
$281K Buy
+6,345
New +$305K 0.01% 51

Other funds holding VAL

Antipodes Partners's VAL Position: Q2 2026 in Review

Antipodes Partners increased its Valaris (VAL) stake by 29% in Q2 2026, buying an estimated $21M and bringing the position to 996,450 shares worth $72.3M. The position accounts for 1.33% of the portfolio, ranked #36.

Antipodes Partners first reported a position in VAL in Q4 2024 and has held it in 7 quarters since. The position peaked at $75.6M in Q1 2026. 335 funds tracked by Wall St. Rank hold VAL as of Q2 2026.

  • Antipodes Partners held 996,450 shares of Valaris worth $72.3M as of Q2 2026.
  • Antipodes Partners bought 225,458 Valaris shares in Q2 2026, an estimated $21M.
  • Valaris made up 1.33% of Antipodes Partners's portfolio in Q2 2026, its #36 holding.
  • Antipodes Partners first reported a position in Valaris in Q4 2024 and has held it in 7 quarters since.
  • Antipodes Partners's Valaris position peaked at $75.6M in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Valaris as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.